Barriers to Prescribing Crizotinib Following FDA Approval

JCO Oncology Practice Podcast
10/07/2012 28 min
Barriers to Prescribing Crizotinib Following FDA Approval

Listen "Barriers to Prescribing Crizotinib Following FDA Approval"

Descargar episodio Ver en sitio original

Episode Synopsis

by Robert S. Miller, MD. Dr. Nathan Pennell discusses some of the interesting obstacles he encountered when trying to prescribe crizotinib for 3 patients with ALK positive non-small cell lung cancer in the first few weeks following FDA approval in 2011.

More episodes of the podcast JCO Oncology Practice Podcast

A Podcast About Podcasts: Podcasts as Educational Tools for Providers (and Patients) 21/10/2025
Advance Care Planning: How Can We Improve Access and Uptake? 20/10/2025
2025 ASCO Quality: Creating a Statewide Cancer Drug Repository Network to Improve Access and Affordability 11/10/2025
“Mainstreaming” Germline Genetic Testing: How Nongenetics Providers Can Help Fill the Workforce Gap 15/09/2025
Promoting Resilience in Adolescents and Young Adults (AYAs) with Cancer via Developmentally Targeted, Evidence-Based Interventions 18/08/2025
Incomplete Reporting and Toxicity-Minimizing Language in Oncology 21/07/2025
Park the Parking: Patient and Caregiver Perspectives on Transportation Barriers in Cancer 16/06/2025
Pregnancy and Breast Cancer 19/05/2025
Treatment De-escalation for Favorable Risk Breast Cancer 21/04/2025
Prior Authorization: How Did We Get Here and Where Are We Going? 17/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA